Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect

Bone Marrow Transplantation volume 44, pages 325–326 (2009)Cite this article

To assess the impact of high TRM in our cohort on the long-term outcomes, we reanalyzed the survival after excluding patients that died within the first 100 days (six in allogeneic group and three in the autologous group). We found a median PFS of 1.8 years in the autologous group and 8.2 years in the allogeneic group (P=0.003). Similarly, we found a trend toward improved OS in the allogeneic group; 5.8 versus 10 years (P=0.21). The superior long-term PFS and lower relapse rate in the allogeneic group strongly suggest a GVM effect. However, the early TRM in the allogeneic group offsets the OS benefit. This was more evident after the exclusion of patients that died within first 100 days. It may be appropriate to revisit myeloablative allogeneic transplantation as a treatment option for multiple myeloma in particular in the era of novel agents where the initial overall response to induction therapy exceeds 80%.8 High-risk patients with unfavorable cytogenetics, high-risk gene expression profiling or relapsed disease may be appropriate candidates for such approach in prospective clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Bensinger WI . Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Baillière's best practice & research. Clin Haematol 2007; 20: 783–795.

    CAS  Google Scholar 

  2. Miura Y, Azuma T, Kusumi E, Matsumura T, Kami M, Komatsu T . Graft-versus-myeloma effects in reduced-intensity cord blood transplantation. Int J Hematol 2007; 86: 463–465.

    Article  PubMed  Google Scholar 

  3. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936.

    Article  CAS  Google Scholar 

  4. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F et al. Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2008; e-pub ahead of print December 8.

  5. Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112: 3914–3915.

    Article  CAS  PubMed  Google Scholar 

  6. Bahlis NJ, Stewart DA, Savoie ML, Brown C, Daly A, Chaudhry A et al. Fludarabine-busulfan conditioning and in vivo T-cell depletion with reduced dose of ATG followed by allografting induces durable responses in patients with advanced multiple myeloma with no grade III–IV aGvHD. ASH Annual Meeting Abstracts 2006; 108: 3029.

    Google Scholar 

  7. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–1993 and 1994–1998 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    Article  CAS  PubMed  Google Scholar 

  8. Palumbo A, Rajkumar SV . Treatment of newly diagnosed myeloma. Leukemia 2008; e-pub ahead of print November 13.

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, University of Michigan, Ann Arbor, MI, USA

    Y Khaled, S Mellacheruvu, P Reddy, E Peres & S Mineishi

Authors
  1. Y Khaled
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Mellacheruvu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Peres
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Mineishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Khaled.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khaled, Y., Mellacheruvu, S., Reddy, P. et al. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect. Bone Marrow Transplant 44, 325–326 (2009). https://doi.org/10.1038/bmt.2009.14

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.14

Search

Advanced search

Quick links